banner2013d

Deceptive Imprinting

dreamstime_12929493 dreamstime_3181230

 

Antigenic variation or “Deceptive Imprinting” is a common strategy by which many disease pathogens and cancer cells evade conventional vaccine strategies as well as host immune responses. The immune system has evolved to detect a register of molecular shapes that stimulate both cellular (helper and cytotoxic T cells) and humoral (B cells and antibodies) immune effector activities to neutralize the more common shapes shared by microbial and cellular invaders, which might disrupt the hosts’ physiology. Vaccine resistant pathogens have developed the ability to subvert these effector responses by displaying and presenting chemical shapes and sequences that have higher antigenic indexes than surrounding molecular structures to “decoy” the immune system. As a pathogen invades a host, the immune system preferentially makes a response to these decoy epitopes ignoring the rest of the pathogen’s structure.

The evolutionary success of pathogens employing immune decoying is the presentation of highly immunogenic epitopes, which can also undergo antigenic variation. This decoying effect is termed “Deceptive Imprinting” after the classic example of goslings imprinting on Konrad Lorenz. Such epitopes are often adjacent to those that are more conserved and serve more important structural and functional activities of the pathogen such as adhesion, binding, colonization, and/or virulence factors. This strategy keeps the immune system effectively misdirected from critical functional domains by establishing an antigenic hierarchy between genetically unstable decoy epitopes and other conserved surface structures of the pathogen. This phenomenon also appears to greatly reduce the polyclonal multi-epitope immune response to the pathogen effectively reducing the immune response to a more oligoclonal, single-epitope restricted fashion. Such a restricted response favors the emergence of immune escape mutants and is analogous to single antibiotic or anti-viral chemotherapy that often leads to drug resistant pathogens.

For further information, please contact: Dr. Gregory J. Tobin:  tobin@bmi-md.com

Research & Development

dreamstime_1923964Respiratory disease accounts for an estimated 75 to 80% of all acute morbidity in the U.S. population and approximately 80% of these are due to viruses. The major causes of acute respiratory disease include influenza virus, rhinovirus, respiratory syncytial virus, parainfluenza virus, adenovirus, and respiratory coronavirus. BMI’s vaccine efforts are focused on influenza virus and rhinovirus.
Learn more:  Influenza Virus  | Rhinovirus

Company News

blk triangleFall 2012: BMI has been awarded a contract from the Henry M. Jackson Foundation for the Advancement of Military Medicine.
blk triangleSpring 2012: BMI announces award of a grant from the Bill and Melinda Gates Foundation Grand Challenges Exploration Poliovirus Eradication program.
blk triangleJune 2011: BMI announces collaborative research agreement with Crucell-BV for development of a universal influenza vaccine
blk triangleNov. 2010: BMI announces collaborative research agreement with GSK-Biologicals for development of an immune refocused vaccine for respiratory infection
blk triangleSept 2010: BMI is awarded a Qualifying Therapeutic Discovery Project Award
blk triangleJune 2010: BMI is awarded a Small Business Innovative Research Grant from the NIH for vaccine development
blk triangleNov. 2009: BMI is a prime contractor in the Fundamentals of Biology Program of DARPA/DSO for the study of modularity in biological systems